Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro

Lara Kristina Klauer; Olga Schutti; Selda Ugur; Fatemeh Doraneh-Gard; Daniel Christoph Amberger; Nicole Rogers; Doris Krämer; Andreas Rank; Christoph Schmid; Britta Eiz-Vesper; Helga Maria Schmetzer

doi:10.1159/000516886

. 2021 Jul 7;49(1):44–61. doi: 10.1159/000516886

Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro

Lara Kristina Klauer ^a, Olga Schutti ^a, Selda Ugur ^a, Fatemeh Doraneh-Gard ^a, Daniel Christoph Amberger ^a, Nicole Rogers ^a, Doris Krämer ^b, Andreas Rank ^c, Christoph Schmid ^c, Britta Eiz-Vesper ^d, Helga Maria Schmetzer ^a,^*

PMCID: PMC8832209 PMID: 35221867

Abstract

Introduction

Myeloid leukaemic blasts can be converted into leukaemia-derived dendritic cells (DCleu), characterised by the simultaneous expression of dendritic- and leukaemia-associated antigens, which have the competence to prime and enhance (leukaemia-specific) immune responses with the whole leukaemic antigen repertoire. To display and further specify dendritic cell (DC)- and DCleu-mediated immune responses, we analysed the interferon gamma (IFNy) secretion of innate and adaptive immune cells.

Methods

DC/DCleu were generated from leukaemic whole blood (WB) with (blast)modulatory Kit-I (granulocyte-macrophage colony-stimulating factor [GM-CSF] + Picibanil [OK-432]) and Kit-M (GM-CSF + prostaglandin E1) and were used to stimulate T cell-enriched immunoreactive cells. Initiated anti-leukaemic cytotoxicity was investigated with a cytotoxicity fluorolysis assay. Initiated IFNy secretion of T, NK, CIK, and iNKT cells was investigated with a cytokine secretion assay (CSA). IFNy positivity was additionally evaluated with an intracellular cytokine assay (ICA). Recent activation of leukaemia-specific cells was verified through addition of leukaemia-associated antigens (LAA; WT-1 and Prame)

Results

We found Kit-I and Kit-M competent to generate mature DC and DCleu from leukaemic WB without induction of blast proliferation. Stimulation of immunoreactive cells with DC/DCleu regularly resulted in an increased anti-leukaemic cytotoxicity and increased IFNy secretion of T, NK, and CIK cells, pointing to the significant role of DC/DCleu in leukaemia-specific alongside anti-leukaemic reactions. Interestingly, an addition of LAA did not further increase IFNy secretion, suggesting an efficient activation of leukaemia-specific cells. Here, both the CSA and ICA yielded comparable frequencies of IFNy-positive cells. Remarkably, the anti-leukaemic cytotoxicity positively correlated with the IFNy secretion in TCD3+, TCD4+, TCD8+, and NKCD56+ cells.

Conclusion

Ultimately, the IFNy secretion of innate and adaptive immune cells appeared to be a suitable parameter to assess and monitor the efficacy of in vitro and potentially in vivo acute myeloid leukaemia immunotherapy. The CSA in this regard proved to be a convenient and reproducible technique to detect and phenotypically characterise IFNy-secreting cells. In respect to our studies on DC-based immunomodulation, we were able to display the potential of DC/DCleu to induce or improve leukaemia-specific and anti-leukaemic activity.

Keywords: Leukaemia-derived dendritic cells, Acute myeloid leukaemia, Anti-leukaemic functionality, Leukaemia-specific cells, Cytokine secretion assay

Introduction

Acute myeloid leukaemia (AML) is a malignant disorder of haematopoietic stem cells characterised by the uncontrolled clonal expansion of abnormally differentiated myeloid blasts. Displacing the physiological haematopoiesis, the accumulation of leukaemic blasts causes typical complications such as erythrocytopenia, thrombocytopenia, and leukocytopenia [1, 2]. Standard therapy for AML consists of chemotherapy with or without allogeneic haematopoietic stem cell transplantation [3, 4]. With overall 5-year survival rates of 28.7%, mainly due to infections and relapses initiated by leukaemic stem cells and residual blasts, the outcome though remains unsatisfactory [5, 6, 7].

In recent years, immunotherapeutic approaches in the treatment of AML have gained attention. Different strategies have been developed with the attempt to redirect the immune system in order to overcome the leukaemic immune escape and enforce a tumour-specific immune response. One of the most auspicious approaches in this regard involves the use of dendritic cell (DC)-based vaccines [8, 9, 10, 11]. DCs are some of the most potent antigen-presenting cells of the immune system. As they link the innate and the adaptive immune system, they are pivotal in initiating and regulating an antigen-specific immune response [12, 13]. As such, DCs can be exploited to present tumour antigens in order to induce a potent anti-tumour immunity.

DCs can be generated ex vivo from leukaemic myeloid blasts resulting in mature leukaemia-derived DC (DC_leu) [14, 15, 16], characterised by the simultaneous expression of dendritic cell antigens, leukaemia-specific antigens, and CCR7 as maturation and migration marker [17, 18]. Thus, presenting the whole leukaemic antigen repertoire, mature DC_leu have the competence to activate T cells and likely natural killer cells (NK cells), cytokine-induced killer cells (CIK cells), and invariant natural killer cells (iNKT) to (re)gain leukaemia-specific activity [15, 16, 18, 19, 20].

Leukaemia-specific activity or rather cytotoxicity implies a complex synergy of the innate and adaptive cellular immune system as well as the humoral immune system. Cytotoxicity is exerted by various innate and adaptive immune cells via different mechanisms: through the (rather early and fast) release of the cytolytic molecules perforin and granzyme by degranulation, through the (rather late and slow) interaction with the Fas ligand (FasL) and TNF-related apoptosis-including ligand (TRAIL), and/or through the secretion of tumour necrosis factor alpha (TNFa) and interferon gamma (IFNy) [21, 22, 23]. Especially the latter, IFNy, has a wide-ranging role: it is not only essential to regular immunity, promoting innate and adaptive immune responses and thereby licensing immune cells to exert cytotoxicity, but also strongly associated with anti-tumour immunity, promoting tumour surveillance, recognition, and elimination [24]. However, it has been noted before that under certain circumstances IFNy can also stimulate immune-suppressive mechanisms in tumour cells, including upregulation of indoleamine 2,3-dioxygenase and of checkpoint inhibitors such as programmed cell-death ligand 1, leading to immune escape [25, 26].

In the early phase of an immune response, IFNy is mainly secreted by innate immune cells such as NK, iNKT, DC, and macrophages upon activation [27, 28]. It not only stimulates innate immune cells by enhancing their effector mechanisms and IFNy secretion, but also facilitates tumour recognition and elimination. By up-regulation of the major histocompatibility complex (MHC) class I and II antigen- and cross-presentation pathways, as well as the MHC-II expression on classically non-MHC-II-expressing cells, it increases the perceptibility of tumour cells to adaptive immune cells. Moreover, by up-regulation of the expression of FasR, FasL, TRAIL, caspase-1, −3, −7, −8, and BIM and down-regulating the expression of survivin, it increases the susceptibility of tumour cells to extrinsic and intrinsic pathways of apoptosis [25, 26, 29, 30, 31, 32, 33]. Importantly, by promoting the differentiation, proliferation, and activation of helper T cells type 1 (Th1) and cytotoxic T cells (Tc), IFNy links the innate and adaptive immunity, thereby commencing the advanced phase of an immune response. Moreover, it inhibits the differentiation of helper T cells type 2 (Th2) and regulatory T cells [26, 27, 28, 34]. In the advanced phase of an immune response, IFNy is mainly secreted by adaptive immune cells such as Th1 and Tc cells upon primary activation by DC or secondary activation by its specific antigen. IFNy thereupon not only stimulates adaptive immune cells by enhancing their effector mechanisms and IFNy secretion, but also innate immune cells [27, 28, 35]. That way, IFNy creates a positive feedback loop and, together with further cytokines, is able to stimulate and sustain an effective immune response, incorporating both innate and adaptive immune cells.

IFNy is considered as sine qua non for the immune system. It is an important mediator of the innate and adaptive immunity and plays a pivotal role in anti-tumour immunity. A blockade of this critical cytokine restrains an effective immune defence [36, 37]. This inseparable connection between IFNy and cell-based immunity has lead us to hypothesise that IFNy could be a suitable parameter to display leukaemia-specific activity and cytotoxicity. Particularly in respect to future applications, IFNy readouts might have the potential to be a convenient parameter to assess and monitor the efficacy of AML immunotherapy.

The aim of the study was to generate DC/DC_leu with immunomodulatory Kit-I and Kit-M (DC/DC_leu-Kit-I and DC/DC_leu-Kit-M) from leukaemic whole blood (WB) and therewith stimulate autologous T cell-enriched immunoreactive cells. We investigated the resulting anti-leukaemic cytotoxicity with a cytotoxicity fluorolysis assay (CTX) and the resulting IFNy secretion of innate and adaptive immune cells with a cytokine secretion assay (CSA). IFNy production was additionally evaluated with an intracellular cytokine assay (ICA). Ultimately, we correlated the IFNy secretion with the anti-leukaemic cytotoxicity of DC/DC_leu-stimulated immunoreactive cells.

Material and Methods

Sample Collection

Sample collection was conducted after obtaining written informed consent of the blood donor and in accordance with the World Medical Association Declaration of Helsinki and the ethic committee of the Ludwig Maximilian University Hospital Munich (vote No. 33905). Samples in form of heparinised peripheral WB were provided by the University Hospitals of Augsburg, Oldenburg, and Munich.

Patients' Characteristics

Blood samples were obtained from AML patients (n = 19) with a mean age of 62.2 years (range 29–98 years) and a female-to-male ratio of 1:1.4, and from healthy volunteers (n = 4) with a mean age of 29.3 (range 16–57 years) and a female-to-male ratio of 1:1. AML patients were characterised by the French-American-British (FAB) classification (M1-M7), the aetiology (primary AML, secondary AML), the stage of disease (first diagnosis, relapse), the blast phenotype, the blast frequency in peripheral blood, and the cyto- and molecular genetics. An overview is given in Table 1.

Table 1.

Patients' characteristics

Patient No.	Age	Sex	FAB type	Stage	Blast phenotype (CD)	IC blasts, %	Cyto-, molecular genetics	Source	Conducted experiments
AML
1489	55	f	p–M0	dgn	13, 33, 34, 65, 117	61	46, XX; FLT3-ITD mut, NMP1 mut	MNC	DCC, MLC, CTX, CSA
1490	65	m	s–M?	dgn	15, 33, 56, 65	46	46, XY; del(20) (q12q13)[12]; NPM1 wt	MNC	DCC, MLC, CTX, CSA
1509	60	m	p–M2	dgn	13, 33, 34, 65, 117	48	46, XY; FLT3-TKD wt, NPM1 mut	WB	DCC, MLC, CTX, CSA, ICA
1511	78	m	p–M4	rel	13, 15, 33, 34, 65, 117	54	FLT3-ITD mut, RUNX1 mut	WB	DCC, MLC, CTX, CSA
1514	68	m	s–M?	dgn	33, 56, 117	36	46, XY; FLT3-TKD wt, NPM1 mut	WB	DCC, MLC, CSA
1515	67	f	p–M2	dgn	33, 34, 65, 117	80	46, XX; FLT3-TKD wt, NPM1 mut	WB	DCC, MLC, CSA
1518	83	f	p–M5	dgn	14, 15, 34, 65	72	46, XX; FLT3-TKD wt, NPM1 mut	WB	DCC, MLC, CSA, ICA
1521	56	m	p–M4	dgn	13, 15, 33, 34, 65, 117	72	46, XY; FLT3-TKD mut, NPM1 mut	WB	DCC, MLC, CTX, CSA
1525	77	m	p–M1	dgn	13, 15, 33, 34, 117	78	46, XY; FLT3-ITD wt, FLT3-TKD mut, NPM1 mut	WB	DCC, MLC, CSA
1526	74	f	p–M?	dgn	15, 33, 34, 56, 65, 117	59	46, XX; FLT3-TKD wt, NPM1 mut	WB	DCC, MLC, CSA
1527	42	m	p–M2	dgn	7, 13, 15, 33, 34, 65, 117	51	46, XY; FLT3-ITD mut, NPM1 mut	WB	DCC, MLC, CTX, CSA, ICA
1531	71	m	p–M4/5	dgn	13, 33, 34, 117	24	n.d.	WB	DCC, MLC, CSA, ICA
1536	61	m	p–M5	dgn	14, 34, 56	73	46, XY; NPM1 mut	WB	DCC, MLC, CTX, CSA
1562	37	m	p–M1	dgn	2, 7, 13, 34, 117	82	46, XY; del(2) (q21), der(14) t(2; 14) (q21; q32)[7]/46,XY[3]; FLT3-TKD mut, RUNX1 mut	WB	DCC, MLC, CTX, CSA
1565	62	f	p–M4	dgn	13, 15, 34, 65, 117	31	46, XX	WB	DCC, MLC, CTX, CSA
1567	98	f	p–M?	dgn	14, 15, 34, 56	57	46,XX del(5q31), del(5q32-33), MECOM rearrangement inv(3) (q21q26.2)/t(3; 3) (q21;q26.2); FLT3-TKD wt, NPM1 wt	WB	DCC, MLC, CTX, CSA
1568	29	m	p–M?	dgn	10, 13, 33, 34	79	46, XY	WB	DCC, MLC, CTX, CSA
1570	36	f	p–M?	dgn	7, 13, 14, 33, 34, 117	33	46, XX; NPM1 mut	WB	DCC, MLC, CTX, CSA
1572	64	f	p–M?	dgn	13, 33, 34, 65, 117	50	46, XX; RUNX1 mut, EZH2 mut, BCOR mut, U2AF1 mut, ASXL1 mut	WB	DCC, MLC, CTX, CSA, ICA

Healthy
1486	57	f						MNC	CSA
1499	21	f						MNC, WB	DCC, MLC, CSA
1505	22	m						MNC, WB	DCC, MLC, CSA
1523	17	m						WB	DCC, MLC, CSA

Open in a new tab

AML patients presented in WB/mononuclear cells (MNC) with an average of 57.6/53.6% leukemic blasts (range 23.7–80.4/45.9–61.2%), 11.4/1.4% T^CD3+ cells (range 0.9–19.4/0.5–2.2%), 3.3/7.6% B^CD19+ cells (range 0.1–3.9/0.7–14.6%), 2.8/0.7% NK^CD56+ cells (range 0.3–8.1/0.5–0.9%), and 5.3/2.7% monocytes^CD14+ (range 0–16.3/1.6–3.7%). In cases with aberrant expression of T, B, NK, or monocytoid antigens, proportions were not included in the analyses.

Cell Characterisation by Flow Cytometry

Flow cytometric analyses were implemented to evaluate and quantify frequencies, phenotypes, and subsets of leukaemic blasts, DCs, monocytes, B cells, T cells, NK cells, CIK cells, and iNKT cells. Abbreviations of all cell types are given in Table 2.

Table 2.

Cells and cell subsets as evaluated by flow cytometry

	Abbreviation of subgroups	Surface marker	Referred to	Abbreviation	Ref.
Blast cells
Blasts	BLA	BLA⁺ (CD15⁺, CD34⁺, CD65⁺, CD117⁺)	WB or MNC	BLA/WB or/MNC	[17]
Proliferating blasts	BLA_prol	BLA⁺DC⁻CD71⁺	BLA	BLA_prol/BLA	[39]

Dendritic cells
Dendritic cells	DC	DC⁺ (CD80⁺, CD206⁺)	WB or MNC	DC/WB	[17]
Leukaemia-derived DC	DC_leu	DC⁺BLA⁺	WB or MNC	DC_leu/WB or /MNC	[17]
			DC	DC_leu/DC
			BLA	DC_leu/BLA
Mature DC	DC_mat	DC⁺CCR7⁺	WB or MNC	DC_mat/WB or /MNC	[18]
			DC	DC_mat/DC
Mature DC_leu	DC_mat-leu	DC⁺BLA⁺CCR7⁺	WB or MNC	DC_leu-mat/WB or /MNC
			DCleu	DC_leu-mat/DC_leu
			DCmat	DC_leu-mat/DC_mat

Monocytoid cells
CD14⁺ monocytes	monocytesCD14+	CD14⁺	WB	monocytesCD14+/WB	[18]

T cells
CD3⁺ pan T cells	TCD3+	CD3⁺	WB or MNC	TCD3+/WB or MNC	[75]
CD4⁺-coexpressing T cells	TCD4+	CD3⁺CD4⁺	CD3⁺	TCD4+/CD3⁺	[75]
CD8⁺-coexpressing T cells	TCD8+	CD3⁺CD8⁺	CD3⁺	TCD8+/CD3⁺	[75]
Naive T cells	T_naive	CD3⁺CD45RO⁻	CD3⁺	T_naive/CD3⁺	[41]
Non-naive T cells	T_non-naive	CD3⁺CD45RO⁺	CD3⁺	_{Tnon-naive/CD3} ⁺	[41]
Central (memory) T cells	T_cm	CD3⁺CD45RO⁺CCR7⁺	CD3⁺	T_cm/CD3⁺	[41]
Effector (memory) T cells	T_em	CD3⁺CD45RO⁺CCR7⁻	CD3⁺	T_em/CD3⁺	[41]
Proliferating T cells − early	T_prol-early	CD3⁺CD69⁺	CD3⁺	T_prol-early/CD3⁺	[75]
Proliferating T cells − late	T_prol-late	CD3⁺CD71⁺	CD3⁺	T_prol-late/CD3⁺	[75]

B cells
CD19⁺ B cells	BCD19+	CD19+	WB or MNC	BCD19+/WB or /MNC	[20]

CIK cells
CD3⁺CD56⁺ CIK cells	CIKCD56+	CD3⁺CD56⁺	WB or MNC	CIKCD56+/WB or /MNC	[20]
CD3⁺CD161⁺ CIK cells	CIKCD161+	CD3⁺CD161⁺	WB or MNC	CikCD161+/WB or /MNC

NK cells
CD3⁻CD56⁺ NK cells	NKCD56+	CD3⁻CD56⁺	WB or MNC	NKCD56+/WB or /MNC	[20]
CD3⁻CD161⁺ NK cells	NKCD161+	CD3⁻CD161⁺	WB or MNC	NKCD161+/WB or /MNC

iNKT cells
6B11⁺ iNKT cells	iNKT	6B11⁺	WB or MNC	iNKT/WB or /MNC	[20]

IFNy-secreting cells
IFNy-secreting CD3⁺ pan T cells		CD3⁺IFNy⁺	CD3⁺	TCD3+IFNy⁺/TCD3+
IFNy-secreting CD4⁺-coexpressing T cells		CD3⁺CD4⁺IFNy⁺	CD3⁺CD4⁺	TCD4+IFNy⁺/TCD4+
IFNy-secreting CD8⁺-coexpressing T cells		CD3⁺CD8⁺IFNy⁺	CD3⁺CD8⁺	TCD8+IFNy⁺/TCD8+
IFNy-secreting CD3⁺CD56⁺ CIK cells		CD3⁺CD56⁺IFNy⁺	CD3⁺CD56⁺	CIKCD56+IFNy⁺/CIKCD56+
IFNy-secreting CD3⁺CD161⁺ CIK cells		CD3⁺CD161⁺IFNy⁺	CD3⁺CD161⁺	CIKCD161+IFNy⁺/CIKCD161+
IFNy-secreting CD3⁻CD56⁺ NK cells		CD3⁻CD56⁺IFNy⁺	CD3⁻CD56⁺	NKCD56+IFNy⁺/NKCD56+
IFNy-secreting CD3⁻CD161⁺ NK cells		CD3⁻CD161⁺IFNy⁺	CD3⁻CD161⁺	NκCD161+lFNy⁺/NKCD161+
IFNy-secreting 6B11⁺ iNKT cells		6B11⁺IFNy⁺	6B11⁺	iNKT⁺IFNy⁺/iNKT⁺

Open in a new tab

Surface marker combinations for flow cytometric staining and analysis.

Cells were stained with various monoclonal antibodies (moAbs) labelled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin-cyanine7 tandem conjugate (PE-Cy7), or allophycocyanin (APC). Antibodies were provided by Beckman Coulter^a (Krefeld, Germany), Becton Dickinson^b (Heidelberg, Germany), Miltenyi Biotec^c (Bergisch Gladbach, Germany), BioLegend^d (Koblenz, Germany), and Santa Cruz Biotechnology^e (Heidelberg, Germany). For analyses FITC-conjugated moAbs CD3^b, CD14^a, CD15^a, CD45RO^a, CD65^a, CD71^a, CD161^b, IPO38^e; PE-conjugated moAbs CD3^a, CD4^b, CD34^a, CD56^a, CD65^c, CD80^a, 6B11^b, IFNy^d; PE-Cy7-conjugated moAbs CD3^a, CD4^a, CD14^b, CD33^a, CD34^a, CD65^c, CD117^a, CD197^b; APC-conjugated moAbs CD3^a, CD14^a, CD19^a, CD34^a, CD56^a, CD69^b, CD117^a, CD206^b, 6B11^d were used. Non-viable cells were detected with 7AAD^b.

In preparation of staining, erythrocytes in WB samples were lysed using lysing buffer (Becton Dickinson) according to the manufacturer's instructions. Staining was performed by a 15-min incubation of cells with the corresponding moAbs in the dark at room temperature using a staining medium containing 95% PBS (Biochrom, Berlin, Germany) and 5% FCS (Biochrom). Intracellular staining (e.g., IPO38, IFNy) was performed with the FIX&PERM Cell Fixation and Cell Permeabilisation Kit (Thermo Fisher Scientific, Darmstadt, Germany).

Stained cells were analysed with the fluorescence-activated cell sorting flow cytometer FACS Calibur (Becton Dickinson) and the acquisition and analysis software CellQuestPro (Becton Dickinson). Isotype controls were conducted according to the manufacturer's instructions.

Sample Preparation

MNC were isolated from WB by density gradient centrifugation using the Ficoll-Hypague technique and a separating solution with a density of 1.077 g/mL (Biocoll, Biochrom). T cells were isolated from MNC using the MACS microbead and column-based immunomagnetic cell separation technology (Miltenyi Biotec) via positive selection of CD3⁺ cells according to the manufacturer's instructions. Purity of isolated T cells was on average 80.5% (range 57.7–95.3%). MNC and T cells, unless directly used, were frozen with 70% RPMI-1640 medium (Biochrom), 20% human serum (HealthCare Europa GmbH, Vienna, Austria), 10% dimethyl sulfoxide (Sigma Aldrich Chemie GmbH, Steinheim, Germany), stored at −80°C and thawed when required.

Dendritic Cell Culture

The generation of DC/DC_leu was performed by the stimulation of MNC or WB with specific response modifiers, including granulocyte-macrophage colony-stimulating factor (GM-CSF) (Sanofi-Aventis, Frankfurt, Germany), interleukin 4 (IL-4) (PeproTech, Berlin, Germany), Picibanil (OK-432) (Chugai Pharmaceutical Co., Kajiwara, Japan), and prostaglandin E1 (PGE₁) (PeproTech). Compositions of DC/DC_leu-generating protocols are given in Table 3.

Table 3.

DC/DCleu-generating protocols

DC/DC_leu protocol	DC/DC_leu source	Composition (total)	Time of addition	Time of culture	Reference
Pici-PGE1	MNC	GM-CSF 500 U/mL	d0	9 days	[38]
		IL-4 250 U/mL	d0
		OK-432 10 μg/mL	d7
		PGE₁ 1 μg/mL	d7

Kit-I	WB	GM-CSF 800 U/mL	d0, d2–3	7–8 days	[Unpublished data]
		OK-432 10 μg/mL	d0, d2–3		European Patent No. 15 801 987.7-1118

Kit-M	WB	GM-CSF 800 U/mL	d0, d2–3	7–8 days	[Unpublished data]
		PGE1 1 μg/mL	d0, d2–3		European Patent No. 15 801 987.7-1118

Mode of action	GM-CSF	Induction of myeloid and DC differentiation			[16, 38]
	IL-4	Induction of DC differentiation
	OK-432	Danger signalling, stimulation of DC differentiation
	PGE₁	Danger signalling, stimulation of DC maturation and migration (via CCR7 expression)

Open in a new tab

GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-4, interleukin 4; OK-432, Picibanil; PGE₁, prostaglandin E₁; d day.

DC/DC_leu from healthy and leukaemic MNC were generated with the DC/DC_leu-generating protocol Pici-_PGE1 [38]. For this, 3–4 × 10⁶ MNC were cultured in 12-multiwell culture plates (ThermoFisher Scientific) and diluted with 2 mL x-vivo 15 medium (Lonza, Basel, Switzerland). Response modifiers were added to the cultures (further referred to as MNC^DC(P)) according to the protocol. A culture without added response modifiers served as negative control (MNC^DC(Control)). A half-medium exchange was carried out every 2–3 days. Cells were harvested after 9 days.

DC/DC_leu from healthy and leukaemic WB were generated with the DC/DC_leu-generating protocols Kit-I and Kit-M [unpublished data] [38]. For this, 500 μL WB (corresponding to 5.0–30.3 × 10⁶ MNC) were cultured in 24-multiwell culture plates (ThermoFisher Scientific) and diluted with 500 μL x-vivo 15 medium. Response modifiers were added to the cultures (further referred to as WB^DC(I), WB^DC(M)) according to the protocol. Likewise, a culture without added response modifiers served as negative control (WB^DC(Control)). Cells were harvested after 7–8 days.

DC cultures as well as subsequent mixed lymphocyte cultures (MLC) were incubated at 37°C, 21% O₂, and 5% CO₂. In some cases, additional cultures were incubated simultaneously in hypoxia-like conditions (37°C, 10% O₂, 10% CO₂).

Flow cytometric analyses of leukaemic blasts, DC, DC_leu, and DC_mat were performed before and after dendritic cell culture (DCC) using a refined gating strategy [unpublished data] [16, 17, 39]. DC_leu were analysed by the co-expression of at least one blast marker (CD15, CD34, CD65, CD117) including lineage-aberrant markers (CD 56) and one DC marker that had not been expressed on naive blasts (CD80, CD206; of which CD80 qualified in 82.4%, CD206 in 94.1%, and both CD80 and CD206 in 76.5% of cases). Maturation of DC/DC_leu was analysed by the further co-expression of CCR7 (Fig. 1A, B). Premise for DC subgroup analyses was the presence of ≥5% DCs in the total cell fraction.

Fig. 1 — Flow cytometric analyses. A Conversion of myeloid blasts into DC_leu through blastmodulatory Kit-I and Kit-M. Exemplary plots show DC_leu, characterised by the co-expression of the blast marker CD117 and the DC marker CD206, in uncultured WB, WB^DC(Control), WB^DC(M), and WB^DC(I). B Gain of maturation through Kit-I and -M. Exemplary plots show DC_mat, characterised by the co-expression of the DC marker CD206 and the maturation marker CCR7, in WB^DC(Control), WB^DC(M), and WB^DC(I). C Gating of IFNy-secreting T^CD3+ (CD3⁺IFNy⁺), T^CD4+ (CD3⁺CD4⁺IFNy⁺), and T^CD8+ (CD3⁺CD4⁻IFNy⁺) cells as detected by CSA. D Comparison of IFNy-secreting T^CD3+ (CD3⁺IFNy⁺) cells in WB^{DC(Control)-MLC}, WB^DC(M)-MLC, and WB^DC(I)-MLC. Abbreviations of all cell types are given in Table 2.

We conducted preliminary experiments to assess the feasibility and comparability of DC/DC_leu generation in different settings. As these experiments and previous studies [unpublished data] [38, 40] affirmed the feasibility and comparability with Pici-_PGE1 in healthy and leukaemic MNC, with Kit-I and Kit-M in healthy and leukaemic WB, as well as under hypoxia-like and normoxia-like conditions (data not shown), further experiments were conducted on leukaemic WB to adapt to more physiological conditions, under normoxia-like conditions.

Mixed Lymphocyte Culture

Consecutive generation of T cell-enriched immunoreactive cells was performed by the stimulation of autologous T cells with DC/DC_leu-containing MNC^DC or WB^DC.

Based on a MNC model, 1 × 10⁶ T cells and a fraction of MNC^DC containing 0.25 × 10⁶ DC/DC_leu were co-cultured in a 24-multiwell culture plate (total cell count 1.7–4.8 × 10⁶ MNC) and diluted in 1 mL RMPI-1640 medium containing 100 U/mL penicillin (Biochrom) and 15% human serum. 50 U/mL IL-2 were added on day 0 and day 2–3 to all cultures (further referred to as MNC^DC(P)-MLC, MNC^{DC(Control)-MLC}). A half-medium exchange was carried out every 2–3 days. Cells were harvested after 7–9 days.

Based on a WB model, 1 × 10⁶ T cells and a fraction of WB^DC containing 0.25 × 10⁶ DC/DC_leu were co-cultured in a 24-multiwell culture plate (total cell count 1.8–9.4 × 10⁶ MNC) and diluted in 1 mL RMPI-1640 medium containing 100 U/mL penicillin. 50 U/mL IL-2 were added on day 0 and day 2–3 to all cultures (further referred to as WB^DC(I)-MLC, WB^DC(M)-MLC, WB^{DC(Control)-MLC}). Cells were harvested after 6–7 days.

Flow cytometric analyses of T-cell subsets were performed before and after MLC using a refined gating strategy [18, 19, 41].

We conducted preliminary experiments to assess the feasibility and comparability of DC/DC_leu stimulation on immunoreactive cells and its resulting anti-leukaemic cytotoxicity in different settings. As these experiments affirmed the feasibility and comparability in (healthy and) leukaemic MNC and WB (data not shown), further experiments were conducted on leukaemic WB to adapt to more physiological conditions.

Cytotoxity Fluorolysis Assay

A fluorolysis assay was performed to analyse the lytic activity of T cell-enriched immunoreactive cells against leukaemic blasts (further referred to as anti-leukaemic cytotoxicity) of MNC^DC-MLC and WB^DC-MLC [18]. Therefore, a fraction of MNC^DC-MLC and WB^DC-MLC containing 1 × 10⁶ T cells (effector cells) and 1 × 10⁶ thawed autologous leukaemic blasts (target cells) were co-cultured (total cell count 2.3–6.0 × 10⁶ MNC) diluted in 1 mL RMPI-1640 medium containing 100 U/mL penicillin and 15% human serum for 3 and 24 h at 37°C, 21% O₂, 5% CO₂. Target cells were stained with FITC-, PE-, or APC-conjugated blast-specific moAbs before culture, and with 7AAD and a defined number of fluorosphere beads (Beckman Coulter) after culture when harvested. All assays were performed in combination with a control, for which effector and target cells were cultured analogously but separated and only merged prior to flow cytometric analyses.

Flow cytometric analyses were performed using a refined gating strategy [18]. Achieved anti-leukaemic cytotoxicity is described as “blast lysis” defined as the percentual difference of viable target cells between the effector-target cell culture and the control, “cases with blast lysis” defined as the proportion of cases with blast lysis >0%, “improved blast lysis” defined as the percentual difference of the blast lysis of WB^DC(I)-MLC or WB^DC(M)-MLC and WB^{DC(Control)MLC}, and “cases with improved blast lysis” defined as the proportion of cases with improved blast lysis >0%.

Cytokine Secretion Assay

For the detection of IFNy-secreting cells in MNC, MNC^DC-MLC, WB and WB^DC-MLC, an IFNy secretion assay (Miltenyi Biotec) was performed. According to the manufacturer's instructions, cells were firstly labelled with an IFNy Catch Reagent (Miltenyi Biotec), a bi-specific moAB directed against the pan-leukocytic marker CD45 and IFNy. By connecting to leukocytes during a non-IFNy-secretion period (10 min, on ice), followed by connecting to IFNy during an IFNy-secretion period (45 min, 37°C), IFNy could be bound to the positive secreting cells. For detection by flow cytometry, cells were secondly labelled with an IFNy-specific PE-conjugated IFNy Detection Antibody (Miltenyi Biotec).

In some cases, an additional stimulation of MNC, MNC^DC-MLC, WB, and WB^DC-MLC was performed prior to the CSA, for which cells were incubated for 4 h with a leukaemia-associated antigen (LAA) suspension containing 50 μg/mL WT-1 (Miltenyi Biotec) and 50 μg/mL PRAME (Miltenyi Biotec) or with 1 μg/mL staphylococcal enterotoxin B (SEB, Sigma Aldrich Chemie GmbH).

For flow cytometric analyses of IFNy-secreting cells, cells were co-stained with FITC-, PE-Cy7-, and APC-conjugated moAbs. Analyses of IFNy-secreting T, NK, CIK, and iNKT cells were performed with a gating strategy described in Figure 1C, D.

We conducted preliminary experiments to assess the feasibility of the CSA in different settings. As these experiments affirmed the feasibility in uncultured and cultured, healthy and leukaemic, MNC and WB, as well as under hypoxia-like and normoxia like conditions, with comparability in MNC and WB and under hypoxia-like and normoxia-like conditions (data not shown), further experiments were conducted on leukaemic WB to adapt to more physiological conditions, under normoxia-like conditions.

Intracellular Cytokine Assay

For the detection of intracellular IFNy in WB and WB^DC-MLC, an intracellular cytokine assay was performed. To avoid cytokine secretion during the assay, cells were firstly incubated with brefeldin A (1000X, BioLegend) concentrated at 1:1,000 for 15 h. Intracellular staining of IFNy subsequently was procured using the FIX&PERM Cell Fixation and Cell Permeabilisation Kit according to the manufacturer's instructions. For flow cytometric analysis of IFNy-producing cells, cells were co-stained with FITC-, PE-Cy7-, and APC-conjugated moAbs. Analyses of IFNy-secreting T, NK, CIK, and iNKT cells were performed with the same gating strategy as used for the CSA.

Statistical Methods

Data is presented as mean ± standard deviation (SD). Statistical comparisons for two groups were performed using the two-tailed t test and the Pearson correlation coefficient. Significance was defined as “not significant” (n.s.) with p values >0.10, as “borderline significant” with p values 0.10 to 0.05, and as “significant” with p values <0.05. Correlation was defined as “negligible” with r values 0.00 to 0.30 (−0.00 to −0.30), as “low” with r values 0.30 to 0.50 (−0.30 to −0.50), as “moderate” with r values 0.50 to 0.70 (−0.50 to −0.70), and as “high” with r values 0.70 to 1.00 (−0.70 to −1.00). Statistical analyses and figures were implemented with GraphPad Prism 8 (GraphPad Software, California, USA) and Pages 8.2 (Apple, California, USA).

Results

Generation of Mature DC/DC_leu from Leukaemic WB without Induction of Blast Proliferation

We were able to generate significantly higher frequencies of DC/WB and DC_leu/WB with Kit-I and Kit-M compared to control, with significantly higher frequencies in WB^DC(I) than WB^DC(M). Differentiating DC_leu in its subgroups showed significantly higher frequencies of DC_leu/BLA as well as of DC_leu/DC in WB^DC(I) and WB^DC(M) compared to WB^DC(Control). Frequencies of DC_leu/BLA and DC_leu/DC did not differ significantly in WB^DC(I) compared to WB^DC(M) (Fig. 1A, 2A, B).

Fig. 2 — Generation of (mature) DC and DC_leu from leukaemic WB with blastmodulatory Kit-I and Kit-M without induction of blast proliferation. Given are the mean ± SD of DC, DC_leu, DC_mat, and DC_mat-leu in the WB fraction and BLA_prol in the blast fraction in WB^DC(I), WB^DC(M), and WB^DC(Control) (A), and the mean ± SD of DC_leu in the DC and blast fraction, DC_mat in the DC fraction, and DC_mat-leu in the DC_mat and DC_leu fraction in WB^DC(I), WB^DC(M), and WB^DC(Control) (B). Statistically significant (p values <0.05) and borderline significant (p values 0.10 to 0.05) differences are given. Abbreviations of all cell types are given in Table 2.

We furthermore evaluated the maturation of DC and found significantly higher frequencies of DC_mat/WB and DC_mat-leu/WB and no significantly different frequencies of DC_mat/DC in WB^DC(I) and WB^DC(M) compared to WB^DC(Control). Differentiating DC_mat-leu in its subgroups showed no significantly different frequencies of DC_mat-leu/DC_mat and no significantly different frequencies of DC_mat-leu/DC_leu in WB^DC(I) and WB^DC(M) compared to WB^DC(Control). Frequencies of DC_mat and DC_mat-leu in depicted cell groups did not differ significantly in WB^DC(I) compared to WB^DC(M) (Fig. 1B, 2A, B).

Reviewing the effect of Kits on the proliferation of non-converted blasts during DCC, we found no significant shift of BLA_prol/BLA in WB^DC(I) and WB^DC(M) compared to WB^DC(Control) (Fig. 2A).

Stimulatory Impact of DC/DC_leu on T Cell-Enriched Immunoreactive Cells

DC/DC_leu and IL-2 Stimulation Increases T-Cell Activation

To assess the potential stimulating effect of generated DC/DC_leu on immunoreactive cells in the presence of IL-2, T-cell compositions were compared before (WB^DC(Control)) and after (WB^DC(I)-MLC, WB^DC(M)-MLC, WB^{DC(Control)-MLC}) MLC. Frequencies of T^CD4+, T^CD8+, T_prol-early, T_prol-late, T_naive, T_non-naive, T_cm, and T_eff cells were analysed in reference to T^CD3+ cells.

We noticed a generally higher activation status of cells in WB^DC(I)-MLC, WB^DC(M)-MLC as well as in WB^{DC(Control)-MLC} compared to WB^DC(Control), characterised by a significant increase of early and late proliferating T cells, a significant shift from naive to non-naive T cells, and a (significant) increase of central and effector memory T cells. T^CD4+ and T^CD8+ cells did not show any significant transformations. When comparing WB^DC(I)-MLC, WB^DC(M)-MLC, and WB^{DC(Control)-MLC}, no significant differences in T cell compositions could be found (Fig. 3).

Fig. 3 — Stimulatory effect of DC/DC_leu on the composition of immunoreactive cells. Given are the mean ± SD of T-cell subsets in the CD3⁺ cell fraction before (WB^DC(Control)) and after (WB^DC(I)-MLC, WB^DC(M)-MLC, WB^{DC(Control)-MLC}) DC/DC_leu stimulation. Statistically significant (p values <0.05) and borderline significant (p values 0.10 to 0.05) differences are given. Abbreviations of all cell types are given in Table 2.

DC/DC_leu Stimulation Increases Anti-Leukaemic Cytotoxicity

We analysed the lytic activity of WB^DC(I)-MLC, WB^DC(M)-MLC, and WB^{DC(Control)-MLC} through CTX after 3 h and 24 h of incubation of effector and leukaemic target cells, to assess the anti-leukaemic cytotoxicity of DC/DC_leu-stimulated immunoreactive cells.

As early as 3 h, we could observe a lysis of target cells in WB^DC(I)-MLC as well as WB^DC(M)-MLC in about a quarter of the cases, but in WB^{DC(Control)-MLC} in about a half of the cases. Average frequencies of lysed blasts were (n.s.) higher in WB^DC(I)-MLC than in WB^DC(M)-MLC and WB^{DC(Control)-MLC} (Fig. 4A). After 24 h, more cases of WB^DC(I)-MLC and WB^DC(M)-MLC, but less cases of WB^{DC(Control)-MLC} attained lysis. Average frequencies of lysed blasts decreased (n.s.) in WB^DC(I)-MLC and WB^{DC(Control)-MLC}, but increased (n.s.) in WB^DC(M)-MLC, whereby frequencies in WB^DC(I)-MLC and WB^DC(M)-MLC were (n.s.) higher than in WB^{DC(Control)-MLC} (Fig. 4C). Notably, in cases without lysis, frequencies of blasts showed no significant difference between WB^DC(I)-MLC, WB^DC(M)-MLC, and WB^{DC(Control)-MLC}.

Fig. 4 — Stimulatory effect of DC/DC_leu on the cytotoxic activity of immunoreactive cells as measured by CTX. Given are the proportions of cases with blast lysis (“% cases with blast lysis”) and the mean ± range of lysed blasts (“% lysed blasts”) in WB^DC(I)-MLC, WB^DC(M)-MLC, and WB^{DC(Control)-MLC} after 3 h (A) and 24 h (C), and the “best” achieved blast lysis after 3 h or 24 h (E); the proportions of cases with an improvement in blast lysis (“% cases with improved blast lysis”) and the mean ± range of improved lysed blasts (“% improved lysed blasts”) in WB^DC(I)-MLC and WB^DC(M)-MLC in relation to WB^{DC(Control)-MLC} after 3 h (B) and 24 h (D), and the “best” achieved improvement in blast lysis after 3 h or 24 h (F).

Concerning the lysis of target cells in WB^DC(I)-MLC and WB^DC(M)-MLC in relation to WB^{DC(Control)-MLC}, after 3 h, we could observe an improvement in lysis in WB^DC(I)-MLC as well as WB^DC(M)-MLC in about half of the cases. Average improved lysed blasts were (n.s.) higher in WB^DC(I)-MLC than in WB^DC(M)-MLC (Fig. 4B). After 24 h, more cases of WB^DC(I)-MLC and WB^DC(M)-MLC attained an improvement in lysis. Average improved lysed blasts in WB^DC(M)-MLC thereby increased (n.s.) to levels of WB^DC(I)-MLC (Fig. 4D). Notably, in cases without an improvement in lysis, frequencies of blasts showed no significant difference between WB^DC(I)-MLC and WB^DC(M)-MLC.

Overall, choosing the best anti-leukaemic cytotoxicity after 3 or 24 h, we found higher numbers of cases with lysis in WB^DC(M)-MLC than in WB^DC(I)-MLC and WB^{DC(Control)-MLC}. Average frequencies of lysed blasts were (n.s.) higher in WB^DC(I)-MLC and WB^DC(M)-MLC than in WB^{DC(Control)-MLC}, with equal averages in WB^DC(I)-MLC and WB^DC(M)-MLC (Fig. 4E). WB^DC(I)-MLC and WB^DC(M)-MLC attained equal proportions of cases with an improvement in lysis and equal averages of improved lysed blasts (Fig. 4F). There was no significant difference in the frequencies of blasts in cases without lysis between WB^DC(I)-MLC, WB^DC(M)-MLC, and WB^{DC(Control)-MLC} and in cases without an improvement in lysis between WB^DC(I)-MLC and WB^DC(M)-MLC.

Stimulatory Impact of DC/DC_leu on the IFNy Secretion of T Cell-Enriched Immunoreactive Cells Detected via CSA

Analysis of IFNy Secretion

The IFNy secretion of innate and adaptive immune cells was determined through CSA before (uncultured WB) and after (WB^DC(I)-MLC, WB^DC(M)-MLC, WB^{DC(Control)-MLC}) DC/DC_leu stimulation. Frequencies of IFNy-secreting T^CD3+, T^CD4+, T^CD8+, CIK^CD56+, NK^CD56+, CIK^CD161+, NK^CD161+, and iNKT cells were analysed.

No Spontaneous Activation of Immunoreactive Cells during DCC and MLC

We compared frequencies of IFNy-secreting immunoreactive cells in uncultured WB to WB^{DC(Control)-MLC}, to assess the effect of cultivation (DCC and MLC). We found low frequencies of IFNy-secreting cells in uncultured WB. Comparing uncultured WB to WB^{DC(Control)-MLC} showed no significant differences, besides significantly lower frequencies of NK^CD161+IFNy⁺/NK^CD161+ in WB^{DC(Control)-MLC} (Fig. 5).

Fig. 5 — IFNy secretion of immunoreactive cells before (uncultured WB) and after (WB^DC(I)-MLC, WB^DC(M)-MLC, WB^{DC(Control)-MLC}) DC/DC_leu stimulation as measured by CSA. Given are the mean ± SD of frequencies of IFNy-secreting T, NK, CIK, and iNKT cells. Statistically significant (p values <0.05) and borderline significant (p values 0.10 to 0.05) differences are given. Abbreviations of all cell types are given in Table 2.

DC/DC_leu Stimulation Increases IFNy Secretion of Adaptive and Innate Immunoreactive Cells

To assess the effect of DC/DC_leu stimulation on the secretion of IFNy, we compared frequencies of IFNy-secreting immunoreactive cells in WB^DC(I)-MLC, WB^DC(M)-MLC to uncultured WB as well as to WB^{DC(Control)-MLC}.

Regarding cells of the adaptive immune system, we found significantly higher frequencies of T^CD3+IFNy⁺/T^CD3+ in WB^DC(I)-MLC and WB^DC(M)-MLC compared to uncultured WB and WB^{DC(Control)-MLC}, with WB^DC(I)-MLC holding significantly higher frequencies than WB^DC(M)-MLC. Moreover, we could detect significantly higher frequencies of T^CD4+IFNy⁺/T^CD4+ and T^CD8+IFNy⁺/T^CD8+ in WB^DC(I)-MLC and WB^DC(M)-MLC compared to uncultured WB and WB^{DC(Control)-MLC}. Frequencies of both cell groups were (n.s.) higher in WB^DC(I)-MLC compared to WB^DC(M)-MLC (Fig. 1C, 5).

Regarding cells of the innate immune system, we found (significantly) higher frequencies of NK^CD56+IFNy⁺/NK^CD56+ and NK^CD161+IFNy⁺/NK^CD161+ in WB^DC(I)-MLC and WB^DC(M)-MLC compared to uncultured WB and WB^{DC(Control)-MLC}, beside NK^CD161+IFNy⁺/NK^CD161+ showing no significant difference compared to uncultured WB and WB^{DC(Control)-MLC}, with (n.s.) higher frequencies in WB^DC(I)-MLC than WB^DC(M)-MLC. Moreover, we could detect (significantly) higher frequencies of CIK^CD56+IFNy⁺/CIK^CD56+ and CIK^CD161+IFNy⁺/CIK^CD161+ in WB^DC(I)-MLC and WB^DC(M)-MLC compared to uncultured WB and WB^{DC(Control)-MLC}, with (n.s.) higher frequencies in WB^DC(I)-MLC than WB^DC(M)-MLC. No significant differences could be found in the frequencies of iNKT⁺IFNy⁺/iNKT⁺ in WB^DC(I)-MLC and WB^DC(M)-MLC compared to WB^{DC(Control)-MLC}, though compared to uncultured WB (Fig. 5).

No Impact of Age, Sex, and Blast Frequency on Stimulation of IFNy Secretion

Overall, the stimulation of IFNy secretion was possible with both DC/DC_leu-Kit-I and -Kit-M and independent from patients' age, sex, or blast frequency (data not shown).

LAA Stimulation Does Not Further Increase IFNy Secretion of DC/DC_leu-Stimulated Immunoreactive Cells

To assess whether DC/DC_leu-stimulated adaptive immunoreactive cells have been subject to LAA-dependent activation, we added the two LAA WT-1 and PRAME to uncultured WB, WB^DC(I)-MLC, WB^DC(M)-MLC, and WB^{DC(Control)-MLC}. The addition of LAA did (n.s.) increase frequencies of IFNy-secreting cells in uncultured WB and WB^{DC(Control)-MLC}, whereas it did not further increase frequencies of IFNy-secreting cells in WB^DC(I)-MLC and WB^DC(M)-MLC (data not shown).

Positive Correlation of IFNy-Positive Immunoreactive Cells Obtained by CSA and ICA

In order to validate frequencies of IFNy-producing immunoreactive cells obtained by CSA, we performed parallel ICAs and correlated the results. There was a significantly high positive correlation (r = 0.793) between frequencies obtained by CSA and frequencies obtained by ICA (Fig. 6). Both the CSA and ICA hereby yielded comparable frequencies of IFNy-positive T^CD3+, T^CD4+, T^CD8+, CIK^CD56+, NK^CD56+, and iNKT cells.

Fig. 6 — Correlation of the IFNy production of immunoreactive cells (T^CD3+, T^CD4+, T^CD8+, CIK^CD56+, NK^CD56+, iNKT cells) obtained by CSA and ICA. Statistically significant (p values <0.05) correlations are given. Abbreviations of all cell types are given in Table 2.

Positive Correlation of IFNy Secretion and Anti-Leukaemic Cytotoxicity of DC/DC_leu-Stimulated Immunoreactive Cells

To assess the relationship between the IFNy secretion and anti-leukaemic cytotoxicity of DC/DC_leu-stimulated immunoreactive cells, we correlated the absolute improvement of IFNy secretion with the relative improvement of blast lysis (= improved blast lysis) in WB^DC(M)-MLC in proportion to WB^{DC(Control)-MLC}. Unfortunately, both groups could not be correlated in WB^DC(I)-MLC due to low case numbers.

The IFNy secretion did not correlate with anti-leukaemic cytotoxicity after 3 h, but after 24 h: within the adaptive immune cells, we found a significantly moderate positive correlation between T^CD3+IFNy⁺/T^CD3+ and blast lysis (r = 0.600) and between T^CD8+IFNy⁺/T^CD8+ and blast lysis (r = 0.596), and a significantly high positive correlation between T^CD4+IFNy⁺/T^CD4+ and blast lysis (r = 0.716) (Fig. 7A–C). Moreover, within the innate immune cells, we found a significantly high positive correlation between NK^CD56+IFNy⁺/NK^CD56+ and blast lysis (r = 0.976). Other innate immune cells showed no further significant correlations (Fig. 7D).

Fig. 7 — Correlation of the absolute improvement of IFNy secretion with the relative improvement of blast lysis (= improved blast lysis) in WB^DC(M)-MLC compared to WB^{DC(Control)-MLC}. Given are the correlation of T^CD3+IFNy⁺/T^CD3+ (A), T^CD4+IFNy⁺/T^CD4+ (B), T^CD8+IFNy⁺/T^CD8+ (C), and NK^CD56+IFNy⁺/NK^CD56+ (D) with blast lysis. Statistically significant (p values <0.05) and borderline significant (p values 0.10 to 0.05) correlations are given. Abbreviations of all cell types are given in Table 2.

Discussion

DC-Based Immunotherapy for AML

Based on the realisation that the immune system can be exploited to take control over AML, different immunological strategies have been developed to prompt a potent anti-leukaemic immunity. Here, targeted immunotherapeutic strategies relying on antibodies, engineered T-cell receptors and T cells engineered to express chimeric antigen receptors have shown promising results [42, 43, 44]. Targeted immunotherapy, however, depends on a competent target antigen to assure on-tumour effectivity but prevent off-tumour toxicity. Yet, selecting a proper leukaemic target antigen proves to be difficult due to a pervasive expression pattern overlapping with healthy tissues and haematopoiesis [10, 43, 45, 46]. However, there are strategies which are able to overcome this obstacle, most notably DC-based strategies. DCs generated from myeloid leukaemic blasts (DC_leu) are able to simultaneously express dendritic- and leukaemia-specific antigens and thereby prime and enhance leukaemia-specific immune responses with the whole leukaemic antigen repertoire ex and in vivo [11, 47, 48, 49, 50, 51, 52], breaking the burden of finding an appropriate target antigen.

DC/DC_leu Generation and Their Stimulatory Impact on the Anti-Leukaemic Activity of T Cell-Enriched Immunoreactive Cells

We generated DC and DC_leu from leukaemic WB ex vivo with immunomodulatory Kit-I and Kit-M. Frequencies of DC and DC_leu were significantly higher in WB^DC(M) and WB^DC(I) compared to WB^DC(Control), with significantly higher frequencies in WB^DC(I) than WB^DC(M). Both DC and DC_leu showed a significant proportion of mature DC. This stimulation of maturation and CCR7-dependent migration to lymph nodes, as achieved by Kit-I and Kit-M, is essential for DC and DC_leu to activate T cells and other immunoreactive cells [53, 54, 55]. Though both Kits are able to generate significant frequencies of DC/DC_leu, it appears that the combination of GM-CSF + Picibanil (OK-432) in Kit-I has a stronger danger signalling and stimulatory impact on DC differentiation than the combination of GM-CSF + PGE₁ in Kit-M, but a similar stimulatory impact on DC maturation. Importantly, the proliferation of non-converted leukaemic blasts was not induced by Kit-I and Kit-M during DCC. All these findings have already been demonstrated in larger studies [unpublished data] [38, 39]. Comparable results were found under hypoxia-like conditions [40].

Through the stimulation of immunoreactive cells with DC/DC_leu we could observe a generally higher activation status in WB^DC(I)-MLC, WB^DC(M)-MLC as well as WB^{DC(Control)-MLC} compared to WB^DC(Control), characterised by a significant increase of proliferating T cells, a significant shift from naive to non-naive T-cell subsets, and a (significant) increase of central and effector memory T cells. This general transformation is most likely caused by the addition of IL-2 to all MLCs, as IL-2 triggers the proliferation and differentiation of T cells as well as the activation and differentiation of other immunoreactive cells [56]. In addition to that, previous larger studies, however, have found an increase of T^CD8+ cells and a corresponding decrease of T^CD4+ cells in WB^DC(I)-MLC and WB^DC(M)-MLC compared to WB^{DC(Control)-MLC} and WB^DC(Control) [38].

Even though the stimulation of immunoreactive cells with DC/DC_leu had no impact on the composition of T-cell subsets, it had an impact on the anti-leukaemic activity. We could demonstrate that the anti-leukemic cytotoxicity of immunoreactive cells could be notably improved through the stimulation with DC/DC_leu-Kit-I and -Kit-M in most of the cases. Interestingly, some cases achieved lysis or improved lysis after 3 h and some cases only after 24 h, whereas average lysis was the highest in WB^DC(I)-MLC after 3 h and in WB^DC(M)-MLC after 24 h. This occurrence might be due to different killing mechanisms of the immunoreactive cells: the early and fast-acting perforin-granzyme pathway and the late and slow-acting Fas/FasL pathway, which can run separately or synergistically [21, 22]. WB^DC(I)-MLC hereby appears to perform via the former pathway, while WB^DC(M)-MLC appears to operate via the latter pathway. Overall, pooling the best anti-leukaemic cytotoxicity after 3 or 24 h, DC/DC_leu-Kit-I and -Kit-M, however, appear to be equally efficient. Taken together, the CTX allows to quantify the acquired anti-leukaemic cytotoxicity, but it does not display participating cells of the immune response, like the CSA does.

Stimulatory Impact of DC/DC_leu on the IFNy Secretion of T Cell-Enriched Immunoreactive Cells

DC/DC_leu activate adaptive immune cells (T^CD4+, T^CD8+) by presenting leukaemia-specific antigens over MHC class I and II [35] and presumably innate immune cells (NK^CD56+, NK^CD161+, CIK^CD56+, CIK^CD161+, iNKT) by yet unknown MHC-unrestricted mechanisms [57, 58], thereby enhancing their effector mechanisms and IFN secretion, the latter also resulting in cross-stimulation. An increase of IFNy secretion upon DC/DC_leu stimulation can hence display functionally active leukaemia-specific cells.

With the CSA we were able to detect and phenotypically characterise IFNy-secreting adaptive and innate immunoreactive cells, and thereby evaluate the effect of DC/DC_leu stimulation. Uncultured leukaemic WB, as a starting point, already showed low frequencies of IFNy-secreting cells representing a physiological (and conceivably partially leukaemia-specific) immunological base activity. Through stimulation of immunoreactive cells by DC/DC_leu-Kit-I and -Kit-M, we were able not only to increase the anti-leukaemic cytotoxicity, but also to significantly increase the IFNy secretion of adaptive immune cells (T^CD3+, T^CD4+, T^CD8+ cells) in WB^DC(I)-MLC and WB^DC(M)-MLC compared to uncultured WB as well as WB^{DC(Control)-MLC}. Further, the IFNy secretion of innate immune cells (CIK^CD56+, NK^CD56+, CIK^CD161+, NK^CD161+ cells) was (significantly) increased in WB^DC(I)-MLC and WB^DC(M)-MLC compared to uncultured WB as well as WB^{DC(Control)-MLC}, beside NK^CD161+ cells showing no significant difference compared to uncultured WB and iNKT cells showing no significant difference compared to WB^{DC(Control)-MLC}. The IFNy secretion induced with DC/DC_leu-Kit-I hereby emerged to be greater than with DC/DC_leu-Kit-M. Noteworthy, the stimulation of IFNy secretion was independent from patients' age, sex, or blast frequency. Overall, we found an increased immunological activity of innate and adaptive immunoreactive cells after DC/DC_leu stimulation, pointing to an induction of leukaemia-specific cells.

Moreover, we compared frequencies of IFNy-secreting cells in uncultured WB and cultured WB^{DC(Control)-MLC} to assess the effect of cultivation on the secretion of IFNy. We could not find significant differences in any cell types, besides lower levels of IFNy-secreting NK^CD161+ cells after cultivation. This might be due to an IL-2-induced expression of lectin-like transcript 1 (LLT1) on various cells, as cross-linking of LLT1 and CD161 on NK^CD161+ cells results in an inhibition of IFNy production and cytotoxicity [59, 60]. However, it seems that cells stimulated with DC/DC_leu-Kit-I and -Kit-M can slightly compensate this effect. In regard to future clinical application, we suppose the effect of IL-2-induced NK^CD161+ inhibition by LLT1 in vitro to be negligible in vivo, as IL-2 was supplemented. Overall, these findings show that no spontaneous activation of immunoreactive cells during DCC and MLC occurs.

We furthermore investigated the effect of LAA (WT-1 and PRAME) stimulation on DC/DC_leu-stimulated adaptive immunoreactive cells. We hypothesised, that the addition of LAA can only increase the IFNy secretion of cells that have not been subject to LAA-dependent activation. Conformably, the addition of WT-1 and PRAME did (n.s.) increase frequencies of IFNy-secreting cells in uncultured WB and WB^{DC(Control)-MLC}. In contrast, the addition of LAA did not further increase frequencies of IFNy-secreting cells in WB^DC(I)-MLC and WB^DC(M)-MLC, affirming that these immunoreactive cells have been subject to activation through leukaemia-specific antigens presented by DC_leu-Kit-I and -Kit-M, in this case the known LAAs WT-1 and PRAME, whereby no further effect was possible. Remarkably, WT-1 and PRAME are only two of hundreds of leukaemic blast antigens presented by DC_leu, giving DC_leu the exceptional potential to initiate a comprehensive leukaemia-specific immune response.

Correlation of IFNy-Positive Cells Obtained by CSA and ICA

In order to validate frequencies of IFNy-producing immunoreactive cells obtained by CSA, we performed parallel ICAs and correlated the results. We found a significantly high correlation of obtained frequencies between both methods. Both the CSA and ICA yielded comparable frequencies of IFNy-positive T^CD3+, T^CD4+, T^CD8+, CIK^CD56+, NK^CD56+, and iNKT cells.

Correlation of IFNy Secretion and Anti-Leukaemic Cytotoxicity of DC/DC_leu-Stimulated Immunoreactive Cells

We conclusively correlated the IFNy secretion with the anti-leukaemic cytotoxicity in WB^DC(M)-MLC and found a significantly positive correlation between the IFNy secretion of T^CD3+, T^CD4+, T^CD8+ as well as NK^CD56+ cells and the 24-h anti-leukaemic cytotoxicity. Though the other immune cells (NK^CD161+, CIK^CD56+, CIK^CD161+ cells) did not show a direct correlation to cytotoxicity, they showed a (n.s.) increased secretion of IFNy pointing towards an increased activity, which may contribute indirectly to the overall leukaemia-specific activity. Ultimately, cytotoxicity remains dependent on the great interaction of various cells, cytokines, and other factors [12, 35]. Nevertheless, IFNy can reflect the cytotoxic activity of T^CD3+, T^CD4+, T^CD8+, and NK^CD56+ cells. With this knowledge, we suppose that IFNy readouts of these specific cell groups are sufficient to assess and monitor the efficacy of AML immunotherapy.

Evaluation of the CSA

There are various techniques to investigate the cytokine production of immune cells on a single cell level, including the CSA, ICA, and Elispot technology. The central technique used in this study was the CSA, which allowed us to detect and phenotypically analyse IFNy-secreting immunoreactive cells on a single cell level and moreover display DC/DC_leu-induced leukaemia-specific activity and cytotoxicity. It hereby presented itself as a convenient, valid, and reliable method [61].

The ICA has, like the CSA, the potential to detect and phenotypical characterise IFNy-producing cells, however, potentially with a lower sensitivity than the CSA, especially when dealing with low frequencies of IFNy-positive cells [61, 62, 63, 64]. Overall though, we and others found the IFNy production obtained by the CSA and ICA highly correlating [65]. Notably, the ICA holds the capacity to simultaneously analyse further cellular markers like TNFa, but, contrary to the CSA, is more time consuming and inevitably kills analysed cells [66]. The Elispot technology, an enzyme-linked cytokine capture assay, enables the detection of IFNy-producing cells with a high sensitivity, but lacks their phenotypical characterisation if cells are not previously sorted into cellular subsets of interest [67]. Noteworthily, the CSA, contrary to the ICA and the Elispot, holds the potential to isolate viable IFNy-expressing cells, if the interest lies in expansion, further functional analyses (e.g., MHC/peptide-tetramer staining), or cell therapy (e.g., adoptive T-cell transfer) [68, 69].

With IFNy assays being able to display leukaemia-specific cells as well as anti-leukaemic cytotoxicity, they are in advantage of regular cytotoxicity assays. Assays like fluorochrome-labelled assays, 51CR-labelled assays, degranulation assays, and LDH assays only allow the evaluation of achieved cytotoxicity but lack the characterisation of overall participating (leukaemia-specific) cells [70, 71, 72]. However, they best depict functionally active Tc, as they directly measure the lysis of target cells [73]. Nonetheless, these assays are often very labour-intensive and unsuited for upscaling as needed in clinical applications. A more specific identification of Tc can only be accomplished by MHC/peptide-tetramer staining, yet this method requires a specific target antigen, in contrary to IFNy and cytotoxicity assays, and does not assure the functionality of the specific T-cell receptor [73, 74].

All in all, the CSA technology holds multiple advantages compared to other cytokine and cytotoxicity assays, especially by combining characterising and functional data.

Conclusion

We were able to describe the potential of DC/DC_leu to induce or improve leukaemia-specific and anti-leukaemic activity through the detection of IFNy-secreting innate and adaptive immune cells ex vivo. The CSA in this regard proved to be a convenient and reproducible technique to detect and phenotypically characterise IFNy-secreting cells. As such, we believe that IFNy could become a very valuable parameter to assess and monitor the efficacy of AML immunotherapy in future clinical applications.

Statement of Ethics

Conflict of Interest Statement

Modiblast Pharma GmbH (Oberhaching, Germany) holds the European Patent 15 801 987.7-1118 and US Patent 15-517627 “Use of immunomodulatory effective compositions for the immunotherapeutic treatment of patients suffering from myeloid leukemias”, in which H.M.S. is involved.

Author Contributions

L.K.K conducted DCC, MLC, CTX, and CSA experiments and all flow cytometric and statistical analyses. O.S., S.U., F.D.-G., and N.R. performed additional DCC, MLC, CTX, and CSA experiments, which were analysed by L.K.K. O.S. conducted ICA experiments, which were analysed by L.K.K. D.K., A.R., and C.S. provided leukaemic whole blood samples and corresponding diagnostic reports. D.C.A. and B.E.-V. supported functionality assays. H.M.S. designed the study. L.K.K and H.M.S. drafted the manuscript.

Acknowledgement

The authors thank patients, nurses, and physicians for their support with sample materials and diagnostic reports. The results presented in this article are part of the doctoral thesis of Lara Kristina Klauer at the University Hospital of the Ludwig Maximilian University Munich.

References

1.Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell. 1991;64((2)):337–50. doi: 10.1016/0092-8674(91)90643-d. [DOI] [PubMed] [Google Scholar]
2.Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol. 2004;50((3)):197–222. doi: 10.1016/j.critrevonc.2003.11.002. [DOI] [PubMed] [Google Scholar]
3.Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129((4)):424–47. doi: 10.1182/blood-2016-08-733196. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392((10147)):593–606. doi: 10.1016/S0140-6736(18)31041-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Acute Leukemias. Springer; 2008. pp. p. 47–56. [DOI] [PubMed] [Google Scholar]
6.Hokland P, Woll PS, Hansen MC, Bill M. The concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target. Br J Haematol. 2019 Oct;187((2)):144–56. doi: 10.1111/bjh.16104. [DOI] [PubMed] [Google Scholar]
7.National Cancer Institute. Cancer Stat Facts: Leukaemia − Acute Myeloid Leukaemia (AML) [Internet] 2020. [cited 11 February 2020]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.
8.Pyzer AR, Avigan DE, Rosenblatt J. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother. 2014;10((11)):3125–31. doi: 10.4161/21645515.2014.982993. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65((4)):798–810. doi: 10.1007/s12026-017-8931-1. [DOI] [PubMed] [Google Scholar]
10.Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol. 2017;10((1)):142. doi: 10.1186/s13045-017-0505-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Ansprenger C, Amberger DC, Schmetzer HM. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)-With a focus on Dendritic cells of leukemic origin (DCleu) Clinical Immunology. 2020:108467. doi: 10.1016/j.clim.2020.108467. [DOI] [PubMed] [Google Scholar]
12.Chaplin DD. Overview of the immune response. Journal of Allergy and Clinical Immunology. 2010;125((2)):S3–S23. doi: 10.1016/j.jaci.2009.12.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1((3)):145–9. doi: 10.1158/2326-6066.CIR-13-0102. [DOI] [PubMed] [Google Scholar]
14.Narita M, Takahashi M, Liu A, Ayres F, Satoh N, Abe T, et al. Generation of dendritic cells from leukaemia cells of a patient with acute promyelocytic leukaemia by culture with GM-CSF, IL-4 and TNF-alpha. Acta Haematol. 2001;106((3)):89–94. doi: 10.1159/000046595. [DOI] [PubMed] [Google Scholar]
15.Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L, et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol. 2004;173((4)):2855–65. doi: 10.4049/jimmunol.173.4.2855. [DOI] [PubMed] [Google Scholar]
16.Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother. 2010;33((2)):185–99. doi: 10.1097/CJI.0b013e3181b8f4ce. [DOI] [PubMed] [Google Scholar]
17.Schmetzer HM, Kremser A, Loibl J, Kroell T, Kolb HJ. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia. 2007;21((6)):1338–41. doi: 10.1038/sj.leu.2404639. [DOI] [PubMed] [Google Scholar]
18.Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, et al. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother. 2010;33((5)):523–37. doi: 10.1097/CJI.0b013e3181d87ffd. [DOI] [PubMed] [Google Scholar]
19.Liepert A, Grabrucker C, Kremser A, Dreyssig J, Ansprenger C, Freudenreich M, et al. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell Immunol. 2010;265((1)):23–30. doi: 10.1016/j.cellimm.2010.06.009. [DOI] [PubMed] [Google Scholar]
20.Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, et al. Significance of frequencies, compositions, and/or antileukemic activity of (DC-stimulated) invariant NKT, NK and CIK cells on the outcome of patients with AML, ALL and CLL. J Immunother. 2017;40((6)):224–48. doi: 10.1097/CJI.0000000000000171. [DOI] [PubMed] [Google Scholar]
21.Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370((6491)):650–2. doi: 10.1038/370650a0. [DOI] [PubMed] [Google Scholar]
22.Hassin D, Garber OG, Meiraz A, Schiffenbauer YS, Berke G. Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology. 2011;133((2)):190–6. doi: 10.1111/j.1365-2567.2011.03426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Martinez-Lostao L, de Miguel D, Al-Wasaby S, Gallego-Lleyda A, Anel A. Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities. Immunotherapy. 2015;7((8)):883–2. doi: 10.2217/imt.15.56. [DOI] [PubMed] [Google Scholar]
24.Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13((2)):95–109. doi: 10.1016/s1359-6101(01)00038-7. [DOI] [PubMed] [Google Scholar]
25.Kursunel MA, Esendagli G. Corrigendum to “The untold story of IFN-γ in cancer biology” [Cytokine Growth Factor Rev. 31 (2016) 73–81] Cytokine Growth Factor Rev. 2017 2017/06;35((97)) doi: 10.1016/j.cytogfr.2017.02.002. [DOI] [PubMed] [Google Scholar]
26.Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018 2018/05/04;9:847. doi: 10.3389/fimmu.2018.00847. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology. 2003 2003/10/02;75((2)):163–89. doi: 10.1189/jlb.0603252. [DOI] [PubMed] [Google Scholar]
28.Schoenborn JR, Wilson CB. Regulation of Interferon-γ During Innate and Adaptive Immune Responses. Advances in Immunology Elsevier. 2007:p. 41–101. doi: 10.1016/S0065-2776(07)96002-2. [DOI] [PubMed] [Google Scholar]
29.Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998 Jul 1;58((13)):2832–7. [PubMed] [Google Scholar]
30.Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001 2001/08/01;49((2)):251–62. doi: 10.1136/gut.49.2.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Ruiz-Ruiz C, LÓPez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-γ in human breast tumour cells. Biochemical Journal. 2002 2002/08/01;365((3)):825–32. doi: 10.1042/BJ20020184. [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Pizzoferrato E, Liu Y, Gambotto A, Armstrong MJ, Stang MT, Gooding WE, et al. Ectopic Expression of Interferon Regulatory Factor-1 Promotes Human Breast Cancer Cell Death and Results in Reduced Expression of Survivin. Cancer Res. 2004 2004/11/15;64((22)):8381–8. doi: 10.1158/0008-5472.CAN-04-2223. [DOI] [PubMed] [Google Scholar]
33.Ruiz-Ruiz C, Ruiz de Almodóvar C, Rodríguez A, Ortiz-Ferrón G, Redondo JM, López-Rivas A. The Up-regulation of Human Caspase-8 by Interferon-γ in Breast Tumor Cells Requires the Induction and Action of the Transcription Factor Interferon Regulatory Factor-1. Journal of Biological Chemistry. 2004 2004/03/01;279((19)):19712–20. doi: 10.1074/jbc.M313023200. [DOI] [PubMed] [Google Scholar]
34.Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008 2008/03;123((3)):326–38. doi: 10.1111/j.1365-2567.2007.02719.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010 2010/02;125((2)):S33–40. doi: 10.1016/j.jaci.2009.09.017. [DOI] [PubMed] [Google Scholar]
36.Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol. 1995 1995/10;58((4)):373–81. [PubMed] [Google Scholar]
37.Shtrichman R, Samuel CE. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol. 2001 2001/06;4((3)):251–9. doi: 10.1016/s1369-5274(00)00199-5. [DOI] [PubMed] [Google Scholar]
38.Amberger DC, Doraneh-Gard F, Gunsilius C, Weinmann M, Möbius S, Kugler C, et al. PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood. Int J Mol Sci. 2019 2019/09/17;20((18)):4590. doi: 10.3390/ijms20184590. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Plett CA, Christoph D, Rabe A, Deen D, Stankova Z, Hirn A, et al. Kits do not induce AML-blasts' proliferation ex vivo. IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts. Eur J Cancer. 2017;5((1)):3–4. [Google Scholar]
40.Doraneh gard F, Amberger D, Weinmann M, Boeck C, Gunsilius C, Kugler C, et al. Standard normoxic versus physiological hypoxic culture of AML patients' (pts) whole blood (WB) samples with immune modulatory kits yields comparable proportions of dendritic cells and functional results. European Journal of Cancer. 2018 2018/03;92:S10–1. [Google Scholar]
41.Vogt V, Schick J, Ansprenger C, Braeu M, Kroell T, Kraemer D, et al. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells. J Immunother. 2014;37((6)):331–47. doi: 10.1097/CJI.0000000000000037. [DOI] [PubMed] [Google Scholar]
42.Geiger TL, Rubnitz JE. New approaches for the immunotherapy of acute myeloid leukemia. Discov Med. 2015 Apr;19((105)):275–84. [PMC free article] [PubMed] [Google Scholar]
43.Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother. Immunotherapy2016. 2016/09/09;65((12)):1433–50. doi: 10.1007/s00262-016-1895-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Biernacki MA, Brault M, Bleakley M. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies. Cancer J. 2019;25((3)):179–90. doi: 10.1097/PPO.0000000000000378. [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012 2012/06/01;26((10)):2186–96. doi: 10.1038/leu.2012.145. [DOI] [PubMed] [Google Scholar]
46.Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, et al. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia. 2014 2014/01/10;28((5)):1167–70. doi: 10.1038/leu.2014.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006 Apr;28((4)):855–61. [PubMed] [Google Scholar]
48.Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006 Apr;133((2)):152–7. doi: 10.1111/j.1365-2141.2006.05997.x. [DOI] [PubMed] [Google Scholar]
49.Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. Hum Vaccin. 2011 2011/05;7((5)):579–84. doi: 10.4161/hv.7.5.14652. [DOI] [PubMed] [Google Scholar]
50.Dong M, Liang D, Li Y, Kong D, Kang P, Li K, et al. Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia. J Int Med Res. 2012;40((4)):1265–74. doi: 10.1177/147323001204000405. [DOI] [PubMed] [Google Scholar]
51.Amberger DC, Schmetzer HM. Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia. Transfusion Medicine and Hemotherapy. 2020 doi: 10.1159/000512452. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Eiz-Vesper B, Schmetzer HM. Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies. Transfusion Medicine and Hemotherapy. 2020 doi: 10.1159/000512729. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Ogihara T, Iinuma H, Okinaga K. Usefulness of immunomodulators for maturation of dendritic cells. International Journal of Oncology. 2004 2004/08/01; [PubMed] [Google Scholar]
54.Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008 2008/05;8((5)):362–71. doi: 10.1038/nri2297. [DOI] [PubMed] [Google Scholar]
55.Platt AM, Randolph GJ. Development and Function of Myeloid Subsets. Elsevier; 2013. Dendritic Cell Migration Through the Lymphatic Vasculature to Lymph Nodes; pp. p. 51–68. [DOI] [PubMed] [Google Scholar]
56.Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012 2012/02/17;12((3)):180–90. doi: 10.1038/nri3156. [DOI] [PubMed] [Google Scholar]
57.Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol ImmunotherImmunotherapy. 2005 2005/11/05;55((9)):1122–31. doi: 10.1007/s00262-005-0089-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
58.Introna M, Correnti F. Innovative Clinical Perspectives for CIK Cells in Cancer Patients. Int J Mol Sci. 2018 2018/01/25;19((2)):358. doi: 10.3390/ijms19020358. [DOI] [PMC free article] [PubMed] [Google Scholar]
59.Aldemir H, Prod'homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, et al. Cutting Edge: Lectin-Like Transcript 1 Is a Ligand for the CD161 Receptor. J Immunol. 2005 2005/12/08;175((12)):7791–5. doi: 10.4049/jimmunol.175.12.7791. [DOI] [PubMed] [Google Scholar]
60.Llibre A, Klenerman P, Willberg CB. Multi-functional lectin-like transcript-1: A new player in human immune regulation. Immunol Lett. 2016 2016/09;177:62–9. doi: 10.1016/j.imlet.2016.07.007. [DOI] [PubMed] [Google Scholar]
61.Desombere I, Meuleman P, Rigole H, Willems A, Irsch J, Leroux-Roels G. The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level. J Immunol Methods. 2004 2004/03;286((1–2)):167–85. doi: 10.1016/j.jim.2004.01.001. [DOI] [PubMed] [Google Scholar]
62.Nomura LE, Walker JM, Maecker HT. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells. Cytometry. 2000 2000/05/01;40((1)):60–8. doi: 10.1002/(sici)1097-0320(20000501)40:1<60::aid-cyto8>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
63.Koehne G, Smith KM, Ferguson TL, Williams RY, Heller G, Pamer EG, et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood. 2002 2002/03/01;99((5)):1730–40. doi: 10.1182/blood.v99.5.1730. [DOI] [PubMed] [Google Scholar]
64.Jaimes MC, Maecker HT, Yan M, Maino VC, Hanley MB, Greer A, et al. Quality assurance of intracellular cytokine staining assays: Analysis of multiple rounds of proficiency testing. J Immunol Methods. 2011 2011/01;363((2)):143–57. doi: 10.1016/j.jim.2010.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Oelke M, Kurokawa T, Hentrich I, Behringer D, Cerundolo V, Lindemann A, et al. Functional Characterization of CD8+ Antigen-Specific Cytotoxic T Lymphocytes after Enrichment Based on Cytokine Secretion: Comparison with the MHC-Tetramer Technology. Scandinavian Journal of Immunology. 2000 2000/12;52((6)):544–9. doi: 10.1046/j.1365-3083.2000.00810.x. [DOI] [PubMed] [Google Scholar]
66.Mair F, Tosevski V. Methods in Molecular Biology. New York: Springer; 2014. Intracellular Staining for Cytokines and Transcription Factors; pp. p. 39–49. [DOI] [PubMed] [Google Scholar]
67.Calarota SA, Baldanti F. Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot Assays. Clinical and Developmental Immunology. 2013;2013:1–8. doi: 10.1155/2013/637649. [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A, et al. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res. 2000 May;6((5)):1997–2005. [PubMed] [Google Scholar]
69.Van Rhijn I, Iwany SK, Fodran P, Cheng TY, Gapin L, Minnaard AJ, et al. CD1b-mycolic acid tetramers demonstrate T-cell fine specificity for mycobacterial lipid tails. Eur J Immunol. 2017 2017/07/31;47((9)):1525–34. doi: 10.1002/eji.201747062. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Kienzle N, Olver S, Buttigieg K, Kelso A. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J Immunol Methods. 2002 2002/09;267((2)):99–108. doi: 10.1016/s0022-1759(02)00150-3. [DOI] [PubMed] [Google Scholar]
71.Lorenzo-Herrero S, Sordo-Bahamonde C, Gonzalez S, López-Soto A. Methods in Molecular Biology. New York: Springer; 2018. CD107a Degranulation Assay to Evaluate Immune Cell Antitumor Activity; pp. p. 119–30. [DOI] [PubMed] [Google Scholar]
72.Lemonnier FA. Evaluating CD8+ T Cell Responses In VitroAntigen Processing. New York: Springer; 2019. pp. p.199–215. [Google Scholar]
73.Michel N, Öhlschläger P, Osen W, Freyschmidt E-J, Guthöhrlein H, Kaufmann AM, et al. T Cell Response to Human Papillomavirus 16 E7 in Mice: Comparison of Cr Release Assay, Intracellular IFN-γ Production, ELISPOT and Tetramer Staining. Intervirology. 2002;45((4–6)):290–9. doi: 10.1159/000067923. [DOI] [PubMed] [Google Scholar]
74.Dolton G, Tungatt K, Lloyd A, Bianchi V, Theaker SM, Trimby A, et al. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology. 2015 2015/08/04;146((1)):11–22. doi: 10.1111/imm.12499. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.Schick J, Vogt V, Zerwes M, Kroell T, Kraemer D, Köhne CH, et al. Antileukemic T-cell Responses Can Be Predicted by the Composition of Specific Regulatory T-cell Subpopulations. J Immunother. 2013 2013/05;36((4)):223–37. doi: 10.1097/CJI.0b013e31829180e7. [DOI] [PubMed] [Google Scholar]

[B1] 1.Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell. 1991;64((2)):337–50. doi: 10.1016/0092-8674(91)90643-d. [DOI] [PubMed] [Google Scholar]

[B2] 2.Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol. 2004;50((3)):197–222. doi: 10.1016/j.critrevonc.2003.11.002. [DOI] [PubMed] [Google Scholar]

[B3] 3.Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129((4)):424–47. doi: 10.1182/blood-2016-08-733196. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B4] 4.Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392((10147)):593–606. doi: 10.1016/S0140-6736(18)31041-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B5] 5.Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Acute Leukemias. Springer; 2008. pp. p. 47–56. [DOI] [PubMed] [Google Scholar]

[B6] 6.Hokland P, Woll PS, Hansen MC, Bill M. The concept of leukaemic stem cells in acute myeloid leukaemia 25 years on: hitting a moving target. Br J Haematol. 2019 Oct;187((2)):144–56. doi: 10.1111/bjh.16104. [DOI] [PubMed] [Google Scholar]

[B7] 7.National Cancer Institute. Cancer Stat Facts: Leukaemia − Acute Myeloid Leukaemia (AML) [Internet] 2020. [cited 11 February 2020]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.

[B8] 8.Pyzer AR, Avigan DE, Rosenblatt J. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother. 2014;10((11)):3125–31. doi: 10.4161/21645515.2014.982993. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B9] 9.Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65((4)):798–810. doi: 10.1007/s12026-017-8931-1. [DOI] [PubMed] [Google Scholar]

[B10] 10.Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol. 2017;10((1)):142. doi: 10.1186/s13045-017-0505-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B11] 11.Ansprenger C, Amberger DC, Schmetzer HM. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)-With a focus on Dendritic cells of leukemic origin (DCleu) Clinical Immunology. 2020:108467. doi: 10.1016/j.clim.2020.108467. [DOI] [PubMed] [Google Scholar]

[B12] 12.Chaplin DD. Overview of the immune response. Journal of Allergy and Clinical Immunology. 2010;125((2)):S3–S23. doi: 10.1016/j.jaci.2009.12.980. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B13] 13.Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1((3)):145–9. doi: 10.1158/2326-6066.CIR-13-0102. [DOI] [PubMed] [Google Scholar]

[B14] 14.Narita M, Takahashi M, Liu A, Ayres F, Satoh N, Abe T, et al. Generation of dendritic cells from leukaemia cells of a patient with acute promyelocytic leukaemia by culture with GM-CSF, IL-4 and TNF-alpha. Acta Haematol. 2001;106((3)):89–94. doi: 10.1159/000046595. [DOI] [PubMed] [Google Scholar]

[B15] 15.Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L, et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol. 2004;173((4)):2855–65. doi: 10.4049/jimmunol.173.4.2855. [DOI] [PubMed] [Google Scholar]

[B16] 16.Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother. 2010;33((2)):185–99. doi: 10.1097/CJI.0b013e3181b8f4ce. [DOI] [PubMed] [Google Scholar]

[B17] 17.Schmetzer HM, Kremser A, Loibl J, Kroell T, Kolb HJ. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia. 2007;21((6)):1338–41. doi: 10.1038/sj.leu.2404639. [DOI] [PubMed] [Google Scholar]

[B18] 18.Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, et al. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother. 2010;33((5)):523–37. doi: 10.1097/CJI.0b013e3181d87ffd. [DOI] [PubMed] [Google Scholar]

[B19] 19.Liepert A, Grabrucker C, Kremser A, Dreyssig J, Ansprenger C, Freudenreich M, et al. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell Immunol. 2010;265((1)):23–30. doi: 10.1016/j.cellimm.2010.06.009. [DOI] [PubMed] [Google Scholar]

[B20] 20.Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, et al. Significance of frequencies, compositions, and/or antileukemic activity of (DC-stimulated) invariant NKT, NK and CIK cells on the outcome of patients with AML, ALL and CLL. J Immunother. 2017;40((6)):224–48. doi: 10.1097/CJI.0000000000000171. [DOI] [PubMed] [Google Scholar]

[B21] 21.Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370((6491)):650–2. doi: 10.1038/370650a0. [DOI] [PubMed] [Google Scholar]

[B22] 22.Hassin D, Garber OG, Meiraz A, Schiffenbauer YS, Berke G. Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology. 2011;133((2)):190–6. doi: 10.1111/j.1365-2567.2011.03426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B23] 23.Martinez-Lostao L, de Miguel D, Al-Wasaby S, Gallego-Lleyda A, Anel A. Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities. Immunotherapy. 2015;7((8)):883–2. doi: 10.2217/imt.15.56. [DOI] [PubMed] [Google Scholar]

[B24] 24.Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13((2)):95–109. doi: 10.1016/s1359-6101(01)00038-7. [DOI] [PubMed] [Google Scholar]

[B25] 25.Kursunel MA, Esendagli G. Corrigendum to “The untold story of IFN-γ in cancer biology” [Cytokine Growth Factor Rev. 31 (2016) 73–81] Cytokine Growth Factor Rev. 2017 2017/06;35((97)) doi: 10.1016/j.cytogfr.2017.02.002. [DOI] [PubMed] [Google Scholar]

[B26] 26.Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018 2018/05/04;9:847. doi: 10.3389/fimmu.2018.00847. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B27] 27.Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology. 2003 2003/10/02;75((2)):163–89. doi: 10.1189/jlb.0603252. [DOI] [PubMed] [Google Scholar]

[B28] 28.Schoenborn JR, Wilson CB. Regulation of Interferon-γ During Innate and Adaptive Immune Responses. Advances in Immunology Elsevier. 2007:p. 41–101. doi: 10.1016/S0065-2776(07)96002-2. [DOI] [PubMed] [Google Scholar]

[B29] 29.Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998 Jul 1;58((13)):2832–7. [PubMed] [Google Scholar]

[B30] 30.Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001 2001/08/01;49((2)):251–62. doi: 10.1136/gut.49.2.251. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B31] 31.Ruiz-Ruiz C, LÓPez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-γ in human breast tumour cells. Biochemical Journal. 2002 2002/08/01;365((3)):825–32. doi: 10.1042/BJ20020184. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B32] 32.Pizzoferrato E, Liu Y, Gambotto A, Armstrong MJ, Stang MT, Gooding WE, et al. Ectopic Expression of Interferon Regulatory Factor-1 Promotes Human Breast Cancer Cell Death and Results in Reduced Expression of Survivin. Cancer Res. 2004 2004/11/15;64((22)):8381–8. doi: 10.1158/0008-5472.CAN-04-2223. [DOI] [PubMed] [Google Scholar]

[B33] 33.Ruiz-Ruiz C, Ruiz de Almodóvar C, Rodríguez A, Ortiz-Ferrón G, Redondo JM, López-Rivas A. The Up-regulation of Human Caspase-8 by Interferon-γ in Breast Tumor Cells Requires the Induction and Action of the Transcription Factor Interferon Regulatory Factor-1. Journal of Biological Chemistry. 2004 2004/03/01;279((19)):19712–20. doi: 10.1074/jbc.M313023200. [DOI] [PubMed] [Google Scholar]

[B34] 34.Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008 2008/03;123((3)):326–38. doi: 10.1111/j.1365-2567.2007.02719.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B35] 35.Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010 2010/02;125((2)):S33–40. doi: 10.1016/j.jaci.2009.09.017. [DOI] [PubMed] [Google Scholar]

[B36] 36.Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol. 1995 1995/10;58((4)):373–81. [PubMed] [Google Scholar]

[B37] 37.Shtrichman R, Samuel CE. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol. 2001 2001/06;4((3)):251–9. doi: 10.1016/s1369-5274(00)00199-5. [DOI] [PubMed] [Google Scholar]

[B38] 38.Amberger DC, Doraneh-Gard F, Gunsilius C, Weinmann M, Möbius S, Kugler C, et al. PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood. Int J Mol Sci. 2019 2019/09/17;20((18)):4590. doi: 10.3390/ijms20184590. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B39] 39.Plett CA, Christoph D, Rabe A, Deen D, Stankova Z, Hirn A, et al. Kits do not induce AML-blasts' proliferation ex vivo. IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts. Eur J Cancer. 2017;5((1)):3–4. [Google Scholar]

[B40] 40.Doraneh gard F, Amberger D, Weinmann M, Boeck C, Gunsilius C, Kugler C, et al. Standard normoxic versus physiological hypoxic culture of AML patients' (pts) whole blood (WB) samples with immune modulatory kits yields comparable proportions of dendritic cells and functional results. European Journal of Cancer. 2018 2018/03;92:S10–1. [Google Scholar]

[B41] 41.Vogt V, Schick J, Ansprenger C, Braeu M, Kroell T, Kraemer D, et al. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells. J Immunother. 2014;37((6)):331–47. doi: 10.1097/CJI.0000000000000037. [DOI] [PubMed] [Google Scholar]

[B42] 42.Geiger TL, Rubnitz JE. New approaches for the immunotherapy of acute myeloid leukemia. Discov Med. 2015 Apr;19((105)):275–84. [PMC free article] [PubMed] [Google Scholar]

[B43] 43.Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother. Immunotherapy2016. 2016/09/09;65((12)):1433–50. doi: 10.1007/s00262-016-1895-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B44] 44.Biernacki MA, Brault M, Bleakley M. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies. Cancer J. 2019;25((3)):179–90. doi: 10.1097/PPO.0000000000000378. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B45] 45.Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012 2012/06/01;26((10)):2186–96. doi: 10.1038/leu.2012.145. [DOI] [PubMed] [Google Scholar]

[B46] 46.Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, et al. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia. 2014 2014/01/10;28((5)):1167–70. doi: 10.1038/leu.2014.14. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47.Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006 Apr;28((4)):855–61. [PubMed] [Google Scholar]

[B48] 48.Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006 Apr;133((2)):152–7. doi: 10.1111/j.1365-2141.2006.05997.x. [DOI] [PubMed] [Google Scholar]

[B49] 49.Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. Hum Vaccin. 2011 2011/05;7((5)):579–84. doi: 10.4161/hv.7.5.14652. [DOI] [PubMed] [Google Scholar]

[B50] 50.Dong M, Liang D, Li Y, Kong D, Kang P, Li K, et al. Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia. J Int Med Res. 2012;40((4)):1265–74. doi: 10.1177/147323001204000405. [DOI] [PubMed] [Google Scholar]

[B51] 51.Amberger DC, Schmetzer HM. Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia. Transfusion Medicine and Hemotherapy. 2020 doi: 10.1159/000512452. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B52] 52.Eiz-Vesper B, Schmetzer HM. Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies. Transfusion Medicine and Hemotherapy. 2020 doi: 10.1159/000512729. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B53] 53.Ogihara T, Iinuma H, Okinaga K. Usefulness of immunomodulators for maturation of dendritic cells. International Journal of Oncology. 2004 2004/08/01; [PubMed] [Google Scholar]

[B54] 54.Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008 2008/05;8((5)):362–71. doi: 10.1038/nri2297. [DOI] [PubMed] [Google Scholar]

[B55] 55.Platt AM, Randolph GJ. Development and Function of Myeloid Subsets. Elsevier; 2013. Dendritic Cell Migration Through the Lymphatic Vasculature to Lymph Nodes; pp. p. 51–68. [DOI] [PubMed] [Google Scholar]

[B56] 56.Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012 2012/02/17;12((3)):180–90. doi: 10.1038/nri3156. [DOI] [PubMed] [Google Scholar]

[B57] 57.Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol ImmunotherImmunotherapy. 2005 2005/11/05;55((9)):1122–31. doi: 10.1007/s00262-005-0089-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58] 58.Introna M, Correnti F. Innovative Clinical Perspectives for CIK Cells in Cancer Patients. Int J Mol Sci. 2018 2018/01/25;19((2)):358. doi: 10.3390/ijms19020358. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B59] 59.Aldemir H, Prod'homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, et al. Cutting Edge: Lectin-Like Transcript 1 Is a Ligand for the CD161 Receptor. J Immunol. 2005 2005/12/08;175((12)):7791–5. doi: 10.4049/jimmunol.175.12.7791. [DOI] [PubMed] [Google Scholar]

[B60] 60.Llibre A, Klenerman P, Willberg CB. Multi-functional lectin-like transcript-1: A new player in human immune regulation. Immunol Lett. 2016 2016/09;177:62–9. doi: 10.1016/j.imlet.2016.07.007. [DOI] [PubMed] [Google Scholar]

[B61] 61.Desombere I, Meuleman P, Rigole H, Willems A, Irsch J, Leroux-Roels G. The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level. J Immunol Methods. 2004 2004/03;286((1–2)):167–85. doi: 10.1016/j.jim.2004.01.001. [DOI] [PubMed] [Google Scholar]

[B62] 62.Nomura LE, Walker JM, Maecker HT. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells. Cytometry. 2000 2000/05/01;40((1)):60–8. doi: 10.1002/(sici)1097-0320(20000501)40:1<60::aid-cyto8>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]

[B63] 63.Koehne G, Smith KM, Ferguson TL, Williams RY, Heller G, Pamer EG, et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood. 2002 2002/03/01;99((5)):1730–40. doi: 10.1182/blood.v99.5.1730. [DOI] [PubMed] [Google Scholar]

[B64] 64.Jaimes MC, Maecker HT, Yan M, Maino VC, Hanley MB, Greer A, et al. Quality assurance of intracellular cytokine staining assays: Analysis of multiple rounds of proficiency testing. J Immunol Methods. 2011 2011/01;363((2)):143–57. doi: 10.1016/j.jim.2010.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B65] 65.Oelke M, Kurokawa T, Hentrich I, Behringer D, Cerundolo V, Lindemann A, et al. Functional Characterization of CD8+ Antigen-Specific Cytotoxic T Lymphocytes after Enrichment Based on Cytokine Secretion: Comparison with the MHC-Tetramer Technology. Scandinavian Journal of Immunology. 2000 2000/12;52((6)):544–9. doi: 10.1046/j.1365-3083.2000.00810.x. [DOI] [PubMed] [Google Scholar]

[B66] 66.Mair F, Tosevski V. Methods in Molecular Biology. New York: Springer; 2014. Intracellular Staining for Cytokines and Transcription Factors; pp. p. 39–49. [DOI] [PubMed] [Google Scholar]

[B67] 67.Calarota SA, Baldanti F. Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot Assays. Clinical and Developmental Immunology. 2013;2013:1–8. doi: 10.1155/2013/637649. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B68] 68.Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A, et al. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res. 2000 May;6((5)):1997–2005. [PubMed] [Google Scholar]

[B69] 69.Van Rhijn I, Iwany SK, Fodran P, Cheng TY, Gapin L, Minnaard AJ, et al. CD1b-mycolic acid tetramers demonstrate T-cell fine specificity for mycobacterial lipid tails. Eur J Immunol. 2017 2017/07/31;47((9)):1525–34. doi: 10.1002/eji.201747062. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B70] 70.Kienzle N, Olver S, Buttigieg K, Kelso A. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J Immunol Methods. 2002 2002/09;267((2)):99–108. doi: 10.1016/s0022-1759(02)00150-3. [DOI] [PubMed] [Google Scholar]

[B71] 71.Lorenzo-Herrero S, Sordo-Bahamonde C, Gonzalez S, López-Soto A. Methods in Molecular Biology. New York: Springer; 2018. CD107a Degranulation Assay to Evaluate Immune Cell Antitumor Activity; pp. p. 119–30. [DOI] [PubMed] [Google Scholar]

[B72] 72.Lemonnier FA. Evaluating CD8+ T Cell Responses In VitroAntigen Processing. New York: Springer; 2019. pp. p.199–215. [Google Scholar]

[B73] 73.Michel N, Öhlschläger P, Osen W, Freyschmidt E-J, Guthöhrlein H, Kaufmann AM, et al. T Cell Response to Human Papillomavirus 16 E7 in Mice: Comparison of Cr Release Assay, Intracellular IFN-γ Production, ELISPOT and Tetramer Staining. Intervirology. 2002;45((4–6)):290–9. doi: 10.1159/000067923. [DOI] [PubMed] [Google Scholar]

[B74] 74.Dolton G, Tungatt K, Lloyd A, Bianchi V, Theaker SM, Trimby A, et al. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology. 2015 2015/08/04;146((1)):11–22. doi: 10.1111/imm.12499. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B75] 75.Schick J, Vogt V, Zerwes M, Kroell T, Kraemer D, Köhne CH, et al. Antileukemic T-cell Responses Can Be Predicted by the Composition of Specific Regulatory T-cell Subpopulations. J Immunother. 2013 2013/05;36((4)):223–37. doi: 10.1097/CJI.0b013e31829180e7. [DOI] [PubMed] [Google Scholar]

PERMALINK

Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro

Lara Kristina Klauer

Olga Schutti

Selda Ugur

Fatemeh Doraneh-Gard

Daniel Christoph Amberger

Nicole Rogers

Doris Krämer

Andreas Rank

Christoph Schmid

Britta Eiz-Vesper

Helga Maria Schmetzer

Abstract

Introduction

Methods

Results

Conclusion

Introduction

Material and Methods

Sample Collection

Patients' Characteristics

Table 1.

Cell Characterisation by Flow Cytometry

Table 2.

Sample Preparation

Dendritic Cell Culture

Table 3.

Fig. 1.

Mixed Lymphocyte Culture

Cytotoxity Fluorolysis Assay

Cytokine Secretion Assay

Intracellular Cytokine Assay

Statistical Methods

Results

Generation of Mature DC/DCleu from Leukaemic WB without Induction of Blast Proliferation

Fig. 2.

Stimulatory Impact of DC/DCleu on T Cell-Enriched Immunoreactive Cells

DC/DCleu and IL-2 Stimulation Increases T-Cell Activation

Fig. 3.

DC/DCleu Stimulation Increases Anti-Leukaemic Cytotoxicity

Fig. 4.

Stimulatory Impact of DC/DCleu on the IFNy Secretion of T Cell-Enriched Immunoreactive Cells Detected via CSA

Analysis of IFNy Secretion

No Spontaneous Activation of Immunoreactive Cells during DCC and MLC

Fig. 5.

DC/DCleu Stimulation Increases IFNy Secretion of Adaptive and Innate Immunoreactive Cells

No Impact of Age, Sex, and Blast Frequency on Stimulation of IFNy Secretion

LAA Stimulation Does Not Further Increase IFNy Secretion of DC/DCleu-Stimulated Immunoreactive Cells

Positive Correlation of IFNy-Positive Immunoreactive Cells Obtained by CSA and ICA

Fig. 6.

Positive Correlation of IFNy Secretion and Anti-Leukaemic Cytotoxicity of DC/DCleu-Stimulated Immunoreactive Cells

Fig. 7.

Discussion

DC-Based Immunotherapy for AML

DC/DCleu Generation and Their Stimulatory Impact on the Anti-Leukaemic Activity of T Cell-Enriched Immunoreactive Cells

Stimulatory Impact of DC/DCleu on the IFNy Secretion of T Cell-Enriched Immunoreactive Cells

Correlation of IFNy-Positive Cells Obtained by CSA and ICA

Correlation of IFNy Secretion and Anti-Leukaemic Cytotoxicity of DC/DCleu-Stimulated Immunoreactive Cells

Evaluation of the CSA

Conclusion

Statement of Ethics

Conflict of Interest Statement

Author Contributions

Acknowledgement

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Generation of Mature DC/DC_leu from Leukaemic WB without Induction of Blast Proliferation

Stimulatory Impact of DC/DC_leu on T Cell-Enriched Immunoreactive Cells

DC/DC_leu and IL-2 Stimulation Increases T-Cell Activation

DC/DC_leu Stimulation Increases Anti-Leukaemic Cytotoxicity

Stimulatory Impact of DC/DC_leu on the IFNy Secretion of T Cell-Enriched Immunoreactive Cells Detected via CSA

DC/DC_leu Stimulation Increases IFNy Secretion of Adaptive and Innate Immunoreactive Cells

LAA Stimulation Does Not Further Increase IFNy Secretion of DC/DC_leu-Stimulated Immunoreactive Cells

Positive Correlation of IFNy Secretion and Anti-Leukaemic Cytotoxicity of DC/DC_leu-Stimulated Immunoreactive Cells

DC/DC_leu Generation and Their Stimulatory Impact on the Anti-Leukaemic Activity of T Cell-Enriched Immunoreactive Cells

Stimulatory Impact of DC/DC_leu on the IFNy Secretion of T Cell-Enriched Immunoreactive Cells

Correlation of IFNy Secretion and Anti-Leukaemic Cytotoxicity of DC/DC_leu-Stimulated Immunoreactive Cells